Fibrobiologics Inc (FBLG)

$1.10 +0.11 (11.11%)
Market Cap 5.16M
Revenue (ttm) 0.00
Net Income (ttm) -18.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 274,600
Avg Vol 522,048
Day's Range N/A - N/A
Shares Out 5.21M
Stochastic %K 26%
Beta 1.16
Analysts Sell
Price Target $8.00

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 671 5150
Address:
455 East Medical Center Boulevard, Suite 300, Houston, United States
WiseGuyInvestin
WiseGuyInvestin May. 13 at 1:25 AM
$FBLG the biggest problem with the company has been and always will be MONEY. They don’t even have one quarter worth of cash! How are they going to survive without diluting to oblivion!
0 · Reply
Darksoul
Darksoul May. 12 at 8:21 PM
$FBLG conference tomorrow. For anyone out there with rib or disk issues.. u gotta at least root for these guys to be successful.
1 · Reply
Niddi
Niddi May. 12 at 7:28 PM
$FBLG This company has so much potential, given the number of clinically useful products for medical conditions that has no satisfactory treatments, I won’t be surprised if it touches $10 by the end of this year. Just my opinion.
1 · Reply
Niddi
Niddi May. 12 at 6:47 PM
$FBLG
0 · Reply
Love_To_Learn
Love_To_Learn May. 12 at 12:47 PM
$FBLG MADE A CHANGE TO U JUST NOW MAKING SERIES A VOLUME CHANGE OFF THIS 4,257 THE 257 MAKING IT 7.6 MILLION
1 · Reply
JustInTimeAlerts
JustInTimeAlerts May. 11 at 8:14 PM
$FBLG next $WOK huge news out
0 · Reply
StockPileAlert
StockPileAlert May. 11 at 7:14 PM
$FBLG @Stock_Catcher dumped on you all as usual
0 · Reply
rshrsh23
rshrsh23 May. 11 at 6:33 PM
$FBLG the issue is its US company... only china bios know how to screw shorts. $WOK .19 to 2.00 lol. These US co's are more concerned with offerings and dilution. China companies run it 500% first
0 · Reply
rshrsh23
rshrsh23 May. 11 at 6:29 PM
$FBLG -20% on "positive news" ... #trash
2 · Reply
Niddi
Niddi May. 11 at 6:08 PM
$FBLG It should take off at one point. Just a matter of time.
0 · Reply
Latest News on FBLG
FibroBiologics expands fibroblast-based platform to target Hantavirus

2026-05-11T14:42:59.000Z - 1 day ago

FibroBiologics expands fibroblast-based platform to target Hantavirus

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

May 11, 2026, 8:30 AM EDT - 2 days ago

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

FibroBiologics CEO Issues Letter to Shareholders

May 5, 2026, 8:30 AM EDT - 8 days ago

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

2026-05-04T21:05:51.000Z - 8 days ago

FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

May 4, 2026, 4:01 PM EDT - 8 days ago

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

2026-05-04T13:30:12.000Z - 8 days ago

FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

May 4, 2026, 8:30 AM EDT - 9 days ago

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics downgraded to Hold from Buy at Maxim

2026-05-04T12:28:08.000Z - 9 days ago

FibroBiologics downgraded to Hold from Buy at Maxim

FibroBiologics reports Q1 net loss roughly ($5M)

2026-04-30T22:00:27.000Z - 12 days ago

FibroBiologics reports Q1 net loss roughly ($5M)

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

Apr 30, 2026, 5:55 PM EDT - 12 days ago

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

Apr 30, 2026, 8:30 AM EDT - 13 days ago

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics announces compliance with all Nasdaq listing requirements

2026-04-20T20:23:12.000Z - 22 days ago

FibroBiologics announces compliance with all Nasdaq listing requirements

FibroBiologics Compliant with All Nasdaq Listing Requirements

Apr 20, 2026, 4:01 PM EDT - 22 days ago

FibroBiologics Compliant with All Nasdaq Listing Requirements

FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split

2026-04-16T14:53:32.000Z - 26 days ago

FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Apr 10, 2026, 8:30 AM EDT - 4 weeks ago

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

FibroBiologics Announces Closing of $3 Million Public Offering

Apr 2, 2026, 4:01 PM EDT - 5 weeks ago

FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics prices $3M public offering

2026-04-01T00:05:13.000Z - 6 weeks ago

FibroBiologics prices $3M public offering

FibroBiologics Announces Pricing of $3 Million Public Offering

Mar 31, 2026, 8:00 PM EDT - 6 weeks ago

FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics manufactures first batch of CYWC628 drug product for trials

2026-03-31T20:41:40.000Z - 6 weeks ago

FibroBiologics manufactures first batch of CYWC628 drug product for trials

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Mar 31, 2026, 4:15 PM EDT - 6 weeks ago

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Fibrobiologics Inc trading halted, news pending

2026-03-27T23:50:16.000Z - 6 weeks ago

Fibrobiologics Inc trading halted, news pending

FibroBiologics files to sell 1.14M shares of common stock, warrants

2026-03-27T21:25:14.000Z - 6 weeks ago

FibroBiologics files to sell 1.14M shares of common stock, warrants

FibroBiologics downgraded to Hold from Buy at D. Boral Capital

2026-03-26T11:21:11.000Z - 6 weeks ago

FibroBiologics downgraded to Hold from Buy at D. Boral Capital

FibroBiologics announces 1-for-20 reverse stock split

2026-03-25T20:50:15.000Z - 6 weeks ago

FibroBiologics announces 1-for-20 reverse stock split

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

Mar 25, 2026, 4:30 PM EDT - 6 weeks ago

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

FibroBiologics announces expansion of wound care platform

2026-03-12T12:48:33.000Z - 2 months ago

FibroBiologics announces expansion of wound care platform

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

Mar 12, 2026, 8:30 AM EDT - 2 months ago

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

FibroBiologics completes site onboarding for Phase 1/2 trial of CYWC628

2026-03-05T13:48:24.000Z - 2 months ago

FibroBiologics completes site onboarding for Phase 1/2 trial of CYWC628

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Mar 5, 2026, 8:30 AM EST - 2 months ago

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics announces issuance of U.S. patent covering fibroblast therapy

2026-03-02T13:48:25.000Z - 2 months ago

FibroBiologics announces issuance of U.S. patent covering fibroblast therapy

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Mar 2, 2026, 8:30 AM EST - 2 months ago

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

FibroBiologics to Present at the BIO Investment & Growth Summit

Feb 26, 2026, 8:30 AM EST - 2 months ago

FibroBiologics to Present at the BIO Investment & Growth Summit

FibroBiologics price target lowered to $4 from $5 at H.C. Wainwright

2026-02-26T11:11:16.000Z - 2 months ago

FibroBiologics price target lowered to $4 from $5 at H.C. Wainwright

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 4:30 PM EST - 2 months ago

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

FibroBiologics granted extension by Nasdaq to regain compliance

2026-02-23T13:40:30.000Z - 2 months ago

FibroBiologics granted extension by Nasdaq to regain compliance

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

Feb 23, 2026, 8:30 AM EST - 2 months ago

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

FibroBiologics Transcript: EGM 2026

Feb 20, 2026, 12:00 PM EST - 2 months ago

FibroBiologics Transcript: EGM 2026

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

Feb 10, 2026, 8:30 AM EST - 3 months ago

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

FibroBiologics issued Canadian patent covering treatment of Cachexia

2026-02-05T13:40:51.000Z - 3 months ago

FibroBiologics issued Canadian patent covering treatment of Cachexia

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Feb 5, 2026, 8:30 AM EST - 3 months ago

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

FibroBiologics to Present at the DealFlow Discovery Conference

Jan 20, 2026, 8:30 AM EST - 4 months ago

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 6, 2026, 8:30 AM EST - 4 months ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Jan 5, 2026, 8:30 AM EST - 4 months ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 31, 2025, 8:30 AM EST - 4 months ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:05 PM EST - 5 months ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 5 months ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Dec 10, 2025, 8:30 AM EST - 5 months ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics Announces Payoff of Outstanding Debt

Nov 26, 2025, 8:30 AM EST - 5 months ago

FibroBiologics Announces Payoff of Outstanding Debt

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 4:05 PM EST - 6 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 6 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 20, 2025, 8:00 AM EST - 6 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 7:03 PM EST - 6 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 6 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:30 PM EDT - 6 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics to Present at Bio-Europe 2025

Oct 24, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at the 2025 ThinkEquity Conference

Oct 14, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 23, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 12, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 11, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Sep 10, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:30 PM EDT - 10 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 28, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 11, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 9, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jul 7, 2025, 4:35 PM EDT - 11 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 4:35 PM EDT - 11 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

FibroBiologics to Present at the BIO International Convention 2025

Jun 16, 2025, 9:50 AM EDT - 11 months ago

FibroBiologics to Present at the BIO International Convention 2025

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Jun 9, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

May 16, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

WiseGuyInvestin
WiseGuyInvestin May. 13 at 1:25 AM
$FBLG the biggest problem with the company has been and always will be MONEY. They don’t even have one quarter worth of cash! How are they going to survive without diluting to oblivion!
0 · Reply
Darksoul
Darksoul May. 12 at 8:21 PM
$FBLG conference tomorrow. For anyone out there with rib or disk issues.. u gotta at least root for these guys to be successful.
1 · Reply
Niddi
Niddi May. 12 at 7:28 PM
$FBLG This company has so much potential, given the number of clinically useful products for medical conditions that has no satisfactory treatments, I won’t be surprised if it touches $10 by the end of this year. Just my opinion.
1 · Reply
Niddi
Niddi May. 12 at 6:47 PM
$FBLG
0 · Reply
Love_To_Learn
Love_To_Learn May. 12 at 12:47 PM
$FBLG MADE A CHANGE TO U JUST NOW MAKING SERIES A VOLUME CHANGE OFF THIS 4,257 THE 257 MAKING IT 7.6 MILLION
1 · Reply
JustInTimeAlerts
JustInTimeAlerts May. 11 at 8:14 PM
$FBLG next $WOK huge news out
0 · Reply
StockPileAlert
StockPileAlert May. 11 at 7:14 PM
$FBLG @Stock_Catcher dumped on you all as usual
0 · Reply
rshrsh23
rshrsh23 May. 11 at 6:33 PM
$FBLG the issue is its US company... only china bios know how to screw shorts. $WOK .19 to 2.00 lol. These US co's are more concerned with offerings and dilution. China companies run it 500% first
0 · Reply
rshrsh23
rshrsh23 May. 11 at 6:29 PM
$FBLG -20% on "positive news" ... #trash
2 · Reply
Niddi
Niddi May. 11 at 6:08 PM
$FBLG It should take off at one point. Just a matter of time.
0 · Reply
thefly2
thefly2 May. 11 at 5:48 PM
$FBLG to many people playing in the china stocks today. Could’ve been a nice runner
0 · Reply
Niddi
Niddi May. 11 at 3:45 PM
$FBLG Great buying opportunity imo.
0 · Reply
rshrsh23
rshrsh23 May. 11 at 3:04 PM
$FBLG losing 90% of value in 2 months is next level incompetence by that management team, lol
0 · Reply
CharlieTFPC
CharlieTFPC May. 11 at 2:55 PM
$FBLG - let’s get some volume here!
0 · Reply
Darksoul
Darksoul May. 11 at 1:54 PM
$FBLG look at volume influx! Lets go
0 · Reply
KardiTheViking
KardiTheViking May. 11 at 1:41 PM
$FBLG this turd. Management should know that kind of PR communicates you do not know where you are going. Probably will RS again this year
0 · Reply
rshrsh23
rshrsh23 May. 11 at 1:08 PM
$FBLG you know hantavirus isnt serious when Pr's on it get sold off hard
1 · Reply
Niddi
Niddi May. 11 at 1:07 PM
$FBLG It’s being heavily shorted/manipulated down imho
0 · Reply
BoomTradesBio
BoomTradesBio May. 11 at 12:57 PM
$FBLG Took some
0 · Reply
thefly2
thefly2 May. 11 at 12:51 PM
$FBLG $TRAW $ODYS
0 · Reply
thefly2
thefly2 May. 11 at 12:44 PM
$TRAW $FBLG
0 · Reply
thefly2
thefly2 May. 11 at 12:37 PM
$FBLG you would think it would be going up on that news
1 · Reply